Duke University

Duke University, through its Office of Research Administration Division, is the prime recipient and administrator of a massive federal research portfolio spanning biomedical research, basic science, clinical trials, and workforce development as a tax-exempt private research university based in Durham, North Carolina. The university competes predominantly in full-and-open federal research funding (no set-aside posture) and serves as a prime recipient on grants and a prime contractor on service and research contracts, with 87% of recent awards in a prime capacity across contracts and grants.

Duke's customer concentration is extreme and agency-specific. The National Institutes of Health dominates the portfolio across multiple institutes: the National Institute of Allergy and Infectious Diseases leads by combined potential value at $2.94 billion across 608 awards, followed by the National Heart Lung and Blood Institute at $1.5 billion across 415 awards, and the National Institute of Child Health and Human Development at $652.4 million across 307 awards. The broader Department of Health and Human Services National Institutes of Health accounts for 1,624 awards. The National Science Foundation places 1,132 awards. Together, these federal customers account for 38% of the award count but substantially higher concentration by dollar value, with HHS NIH institutes representing 82% of combined potential value. This concentration reflects Duke's identity as a major research university rather than a federal contractor in traditional procurement categories.

Duke's capability portfolio centers on biomedical and life sciences research, including virology quality assurance, immunological safety assessment, pediatric clinical trials, regulatory science R&D, cancer research, infectious disease investigation, neuroscience and neurodegenerative disease research, cardiovascular health, computational biology, AI-enabled health innovation, and graduate research training. Recent representative work includes a $33.45 million definitive contract with the National Institute of Allergy and Infectious Diseases for virology quality assurance covering HIV and viral pathogen assays over seven years (one base year plus six one-year options); an $8.3 million delivery order under the NICHD Best Pharmaceuticals for Children Act Pediatric Trials Network IDIQ for bespoke gene therapy consortium clinical trial support; and a $749,762 contract with the FDA for patient science integration into medical device studies. Grant activity is equally substantial: $3 million NSF cooperative agreement for the AI Institute for Edge Computing and Systems (ATHENA); $8 million to serve as coordinating center for the National Child Traumatic Stress Initiative network; and $4.9 billion in cooperative agreement funding for trauma-informed adolescent mental health services and the Duke Artificial Intelligence and Technology Collaboratory for Aging. The university also operates major service infrastructure including clinical research institutes, imaging cores, and biobanks supporting federal research across NIH institutes and other agencies.

Activity has been volatile. Awards per year ran 516 in 2023, surged to 874 in 2024, then declined to 644 in 2025 and 480 in 2026, with only 16 recorded in the partial 2027 data in the source. The combined potential value across all 11,358 awards stands at $6.32 billion, though obligated dollars total $18.2 billion (288% of potential value), indicating substantial prior-year commitments and carryforward. Recompete exposure in the next twenty-four months is substantial: 800 awards with combined potential value of $246.8 million face ultimate completion dates within that window.

Duke operates through an institutional research administration structure rather than as a traditional federal contractor. The Office of Research Administration Division serves as the contracting and grant-receiving entity, executing work across the university's schools and health system. Corporate structure includes Duke University Health System, Inc., Private Diagnostic Clinic PLLC, and Duke Health Lake Norman Regional Medical Center as named subsidiaries involved in clinical service delivery supporting research missions. SCI (Service Contract Inventory) data shows prime invoiced revenue of $260.3 million across FY2022–FY2025, with FY2022 at $54.1 million, FY2023 at $57 million, FY2024 at $77.3 million, and FY2025 at $71.9 million. Government-paid hourly rates on SCI-reportable contracts ran a median of $175.14/hr, with the 10th percentile at $57.44/hr and 90th percentile at $842.59/hr, reflecting a broad research workforce spanning technicians, clinical coordinators, postdoctoral researchers, and faculty. SCI subcontractor engagement is minimal (0% average sub-hours share on prime records), indicating Duke builds its own delivery teams rather than relying on subcontractor labor for service contract work. In its sub-award footprint (13% of recent awards), Duke acts as recipient on NIH grants and prime recipient on clinical consortia awards, receiving sub-awards from Northwestern University, Vanderbilt University Medical Center, Case Western Reserve University, and other academic institutions for collaborative research components.

Duke's federal position is defined by its status as a preeminent research university, not a federal contractor. Its pipeline is driven by competitive merit-review research funding from NIH, NSF, DoD, and civilian agencies; its recompete cliff reflects the natural expiration of multi-year research grants and cooperative agreements; and its growth or decline follows federal research investment priorities and the university's success in attracting competitive awards. The university is neither pursuing nor positioned to compete for traditional federal procurement (IT services, facilities management, logistics) and does not hold GWACs, GSA Schedules, or other government-wide vehicles characteristic of federal service contractors.